Everything below concerns WADA. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
=== Hormonal === Because women have a higher incidence of AD than men, it has been thought that estrogen deficiency during menopause is a risk factor. In a 2025 analysis of the Canadian Longitudinal Study on Aging, earlier age at menopause was linked with lower cognitive performance.
Elevated creatine kinase (CK) levels in the blood (at most ~10 times normal) are typical in sIBM but affected individuals can also present with normal CK levels. Electromyography (EMG) studies display variable abnormalities such as increased insertional activity, increased spontaneous activity (fibrillation potentials and sharp waves), and large/broad or short/narrow motor unit potentials. On EMG, recruitment patterns can be reduced or increased. Findings can vary even within the same muscle of an affected individual. Muscle biopsy may display several common findings including inflammatory cells invading muscle cells, vacuolar degeneration, and inclusion bodies of aggregations of multiple proteins. sIBM is a challenge to the pathologist and even with a biopsy, diagnosis can be ambiguous. A diagnosis of inclusion body myositis was historically dependent on muscle biopsy results. Antibodies to cytoplasmic 5'-nucleotidase (cN1A; NT5C1A) have been strongly associated with the condition. However, other inflammatory conditions, such as lupus, can have a positive anti-NT5C1A. As of 2019, it remains to be established whether a positive anti-NT5C1A antibody test can make muscle biopsy unneeded.
Microglial cells: Microglia are macrophage cells that make up the primary immune system for the CNS. They are the smallest neuroglial cell. Astrocytes: Star-shaped macroglial cells with many processes found in the CNS. They are the most abundant cell type in the brain, and are intrinsic to a healthy CNS. Oligodendrocytes: CNS cells with very few processes. They form myelin sheaths on the axons of a neuron, which are lipid-based insulation that increases the speed at which the action potential, can travel down the axon. NG2 glia: CNS cells that are distinct from astrocytes, oligodendrocytes, and microglia. They serve as the developmental precursors of oligodendrocytes. Schwann cells: The PNS equivalent of oligodendrocytes, they help maintain axons and form myelin sheaths in the PNS. Satellite glial cell: Line the surface of neuron cell bodies in ganglia (groups of nerve body cells bundled or connected together in the PNS) Enteric glia: Found in the enteric nervous system, within the gastrointestinal tract.
Sources: en.wikipedia.org
The amount of octane in each sample is different, but the amount of nonane is the same (in practice this is not a requirement). Due to scaling, the areas of the nonane peak appear to have different areas, but in reality the areas are identical. Therefore, the relative amounts of octane in each sample increases in the order of mixture 1 (least) < mixture 3 < mixture 2 (most). This conclusion is reached because the ratio of the area of octane to that of nonane is the least in mixture 1 and the most, in mixture 2. Mixture 3 has an intermediate ratio. This ratio can be written as
Hacker, Barton C.; Grimwood, James M. (1977). On the Shoulders of Titans - A History of Project Gemini (SP-4203) (PDF) (Report). NASA. Retrieved January 2, 2026. Spaceflight Mission Patches website NASA NSSDC spacecraft details NASA Gemini 4 press kit (65-158) (PDF) (Report). May 21, 1965. Archived from the original (PDF) on June 21, 2009. "GEMINI 4 - Ed White Spacewalk- Dual Camera, Real Speed, Restored Audio" on YouTube The short film Four Days of Gemini 4 is available for free viewing and download at the Internet Archive.
=== Hormonal regulation of insulin secretion === Several hormones can affect insulin secretion. Estrogen is correlated with an increase of insulin secretion by depolarizing the β-cells membrane and enhancing the entry of Ca2+. In contrast, growth hormone is known to lower the serum level of insulin by promoting the production of insulin-like growth factor-I (IGF-I). IGF-I, in turn, suppresses the insulin secretion.
Sources: en.wikipedia.org
Most awards exclude managerial staff, and must exclude people based on the "seniority of their role" who were traditionally not covered, while "high income earners", paid over $167,500 in 2023, can agree to be exempt from an award if they have a guarantee of annual earnings. This means that, unless enterprise bargaining covers them, fair pay scales do not constrain rip-off executive pay that diminishes the pay of everyone else. Third, there are enterprise agreements, which are bargained between unions and employers to be higher, and under section 57 will displace any sector-wide award. However, in 2012, enterprise agreement coverage reached a peak of merely 27%, and by 2021 coverage fell to 15%, compared to coverages typically over 80% in European Union member states that promote sectoral collective bargaining.
== Structure and contrast with other lipids == The 2,3-sn-glycerol structure and ether bond linkage are two key differences between lipids found in archaea vs those of bacteria and eukarya. The latter use 1,2-sn-glycerol, and mostly, ester bonds. Natural archaeol has 3R, 7R, 11R configurations for the three chiral centers in the isoprenoid chains. There are four structural variations, contributing to the complexity of the membrane lipids in function and properties. The two phytanyl chains can form a 36-member ring to yield macrocyclic archaeol. Hydroxylated archaeol has phytanyl chains hydroxylated at the first tertiary carbon atom, while sesterterpanyl archaeol have the phytanyl side chains with C25 sesterterpanyl chains, substituting at C2 of glycerol or at both carbons. Unsaturated archaeol, with the same carbon skeleton as standard archaeol but one or multiple double bonds in the phytanyl side chains is also discovered.
contact inhibition Also contact inhibition of growth or density-dependent inhibition. In cell culture, the phenomenon by which most normal eukaryotic cells adhering to a planar substratum cease to grow and divide upon reaching a critical cell density, usually as they approach full confluence or come into physical contact with other cells. As a result, many types of cells cultured on plates or in Petri dishes will continue to proliferate until they cover the whole surface of the culture vessel, at which point the rate of cell division abruptly decreases or is arrested entirely, thus forming a confluent monolayer with minimal overlap between neighboring cells, even if the nutrient medium remains plentiful, rather than stacking themselves on top of each other. Transformed or neoplastic cells tend not to respond to cell density in the same way and may continue to proliferate at high densities. This type of density-dependent inhibition of growth is similar to and may occur simultaneously with, but is nonetheless distinct from, the related phenomenon of contact inhibition of movement, whereby moving cells respond to physical contact by temporarily stopping and then reversing their direction of locomotion away from the point of contact.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.